50% of patients stop treatment. 9/10 drugs fail in development. Atlas can explain why.

Semalytix builds Project Atlas, an agentic AI platform that turns the global, multilingual patient voice (Patient Experience Data) into continuous intelligence for medical, commercial and safety teams.

What Project Atlas does

Atlas listens across 26 languages and 144 countries, every day. It is built on 10+ years of supervised AI dedicated to the patient voice, and is used by top-10 pharma across Medical, Commercial, HEOR and Pharmacovigilance teams.

Continuous, by design

Always on between formal review cycles. Patient Experience Data becomes a continuous evidence stream, not a quarterly research project.

Verified at the source

Every signal is traceable to a verified patient utterance. No synthetic data, no engagement-bait, no chatter.

Aware of your objectives

Atlas is briefed on the brand, asset or therapeutic-area objective you are working against, so the same patient corpus answers different teams' questions differently.

Built to enterprise standards

Compliance-first by construction. Supervised guardrails, full provenance, and an architecture DPOs at top-10 pharma sign off on in days, not months.

Three Sentinel agents on Project Atlas

Safety Sentinel: continuous, signal-grade pharmacovigilance from public digital discourse, engineered so no individual case becomes a valid ICSR at the point of MAH access. Outbreak Sentinel: a respiratory-outbreak radar that surfaces ILI, COVID-19 and RSV signals 1 to 6 weeks ahead of traditional surveillance. Adherence Sentinel: hears patients leaving 6 to 10 weeks before refill gaps appear in claims, so brand teams can act while the patient is still reachable.